Daclizumab: A Review in Relapsing Multiple Sclerosis

Daclizumab (Zinbryta®; previously known as daclizumab high-yield process) is a therapeutic monoclonal antibody that has recently been approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Daclizumab is a humanized IgG1 monoclonal antibody directed against CD25, the alpha subunit of the high-affinity interleukin-2 receptor. As demonstrated in the phase III DECIDE trial, once-monthly subcutaneous daclizumab was superior to once-weekly intramuscular interferon (IFN) β-1a in reducing the clinical relapse rate and radiological measures of disease in patients with relapsing-remitting MS. In addition, daclizumab has demonstrated efficacy in reducing disability progression and in improving health-related quality of life in patients with relapsing MS. Ongoing open-label clinical trials indicate that daclizumab’s efficacy is maintained in the longer term (3 years or more). Daclizumab appears to be generally well tolerated, with adverse events of interest (including hepatic, infectious and cutaneous events) generally manageable with regular monitoring and/or standard therapies. The place of daclizumab in MS treatment remains to be fully determined. However, based on available evidence, daclizumab provides a useful alternative option to other currently available disease-modifying therapies in the treatment of relapsing MS.

[1]  Gavin Giovannoni,et al.  Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[2]  P. Fontoura.  Monoclonal antibody therapy in multiple sclerosis , 2010, mAbs.

[3]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[4]  B. Bielekova,et al.  An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2–Driven Activation of CD56bright NK Cells , 2010, The Journal of Immunology.

[5]  Kimberly Umans,et al.  Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study. , 2017, International journal of MS care.

[6]  X. Montalban,et al.  Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial , 2014, The Lancet Neurology.

[7]  I. Nestorov,et al.  Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials , 2016, Clinical Pharmacokinetics.

[8]  Tianxia Wu,et al.  Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis , 2015, Annals of clinical and translational neurology.

[9]  X. Montalban,et al.  Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study , 2016, BMC Neurology.

[10]  D. Kranz.  Faculty Opinions recommendation of A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. , 2011 .

[11]  J. Sheridan,et al.  In vivo maintenance of human regulatory T cells during CD25 blockade , 2014, Journal of Neuroimmunology.

[12]  G. Giovannoni,et al.  Multiple sclerosis: a practical overview for clinicians. , 2010, British medical bulletin.

[13]  D. Arnold,et al.  Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. , 2015, The New England journal of medicine.

[14]  J. Sheridan,et al.  Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials , 2015, Clinical Pharmacokinetics.

[15]  T. Waldmann,et al.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Hana Golding,et al.  Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[17]  R. Nicholas,et al.  Drugs in Development for Relapsing Multiple Sclerosis , 2013, Drugs.

[18]  E. Havrdová,et al.  Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. , 2016, Multiple sclerosis and related disorders.

[19]  J. Elkins,et al.  Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis , 2016, Clinical pharmacology : advances and applications.

[20]  B. Weinshenker,et al.  Disease modifying therapies for relapsing multiple sclerosis , 2016, British Medical Journal.

[21]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[22]  S. Dutta,et al.  Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration , 2014, Clinical Pharmacokinetics.

[23]  I. Nestorov,et al.  Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis. , 2016, British journal of clinical pharmacology.

[24]  Bibiana Bielekova,et al.  Daclizumab Therapy for Multiple Sclerosis , 2012, Neurotherapeutics.

[25]  C. Poser,et al.  Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.

[26]  K. Wyrwich,et al.  Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening , 2014, Multiple sclerosis.

[27]  B. Bielekova,et al.  Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis , 2012, Science Translational Medicine.

[28]  A. Chaudhuri,et al.  Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis , 2015, Practical Neurology.

[29]  H. McFarland,et al.  Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. , 2009, Archives of neurology.

[30]  O. Aktas,et al.  Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis , 2015, Neurotherapeutics.

[31]  K. Garcia,et al.  Structure of the Quaternary Complex of Interleukin-2 with Its α, ß, and γc Receptors , 2005, Science.

[32]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[33]  S. Greenberg,et al.  Daclizumab HYP versus Interferon β-1a across Patient Demographic and Disease Activity Subgroups in the DECIDE Phase 3 Study (P4.007) , 2015 .

[34]  L. Kappos,et al.  Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. , 2016, Multiple sclerosis and related disorders.

[35]  M. Sweetser,et al.  Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis , 2016, Advances in Therapy.

[36]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[37]  G. Gillard,et al.  Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy , 2016, Journal of Neuroimmunology.

[38]  Y. Liu,et al.  Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. , 2017, Multiple sclerosis and related disorders.

[39]  R. R. Robinson,et al.  The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax® , 2016, mAbs.